Custom Search


Login
MY ACCOUNT
support_button
Not a customer? Click Here
Video
Today's Health Headlines
(Reuters Health) - Not all women need Pap tests to look for cells in the cervix that might be malignant. Under new guidelines from U.S. physicians, some women can get a test that looks for the cancer-causing human papilloma virus (HPV).

The mayor of the Chinese city of Changchun resigned on Tuesday, state media reported, after a safety scandal at Changchun-based vaccine maker Changsheng Biotechnology sparked widespread consumer anger.

U.S. Health and Human Services Secretary Alex Azar said it was within his agency's power to eliminate rebates on prescription drug purchases, a key element of the Trump administration's plan to lower prescription medicine costs.

(Reuters Health) - Many pediatricians and family physicians don't discuss the meningococcal B vaccine with teens even though these conversations are recommended to determine whether adolescents should get shots to protect against this lethal infection, a U.S. study suggests.

Most parents are against teen tattoos
Mon, 20 Aug 2018 14:55:31 -0400
(Reuters Health) - Parents who've said "no" to teen tattoos need not feel alone. A new U.S. survey finds that 78 percent of parents wouldn't even consider allowing their teenager to get inked.

(Reuters Health) - Healthy adults who don't keep their LDL-C, or "bad cholesterol," in check are more likely to die prematurely from cardiovascular disease than peers with lower cholesterol levels, a U.S. study suggests.

(Reuters Health) - Black and Hispanic children may be less likely than white kids to survive certain childhood cancers at least in part due to differences in socioeconomic status, a U.S. study suggests.

(Reuters Health) - More retailers may be selling cigarettes to minors than government estimates have suggested, a new study finds.

Heart drugs containing an active ingredient from a second Chinese company are being recalled from the European market after detection of a toxic impurity that may cause cancer.

Roche's Alecensa lung cancer medicine became the latest beneficiary of China's efforts to speed up approvals in the world's second-biggest drug market, which is gaining importance for global pharmaceuticals companies' growth plans.

ADVERTISEMENT